Combined Intravitreal Pharmacosurgery in Patients with Occult Choroidal Neovascularization Secondary to Wet Age-Related Macular Degeneration
Combined Intravitreal Pharmacosurgery in Patients with Occult Choroidal Neovascularization Secondary to Wet Age-Related Macular Degeneration
复制标题
DOI：
10.1159/000235724
复制
发表时间：
2010-01-01
期刊：
影响因子：
2.6
通讯作者：
Koch, F. H.
中科院分区：
文献类型：
--
作者：
Koss, M. J.;Scholtz, S.;Koch, F. H.
Aim: The aim was to investigate the efficacy and safety of combined intravitreal therapy in patients with occult choroidal neovascularization (CNV) secondary to wet age-related macular degeneration (AMD) over 6 months. Methods: In this prospective pilot study of a case series, 106 patients (mean age 75.4 years) with predominantly occult CNVs were treated with a 1.5-ml core pars plana vitrectomy with intravitreal injections of triamcinolone (8 mg), bevacizumab (1.25 mg) and balanced salt solution. The best-corrected visual acuity (BCVA; logMar), central macular thickness (optical coherence tomography), and intraocular pressure (IOP; Goldmann tonometry) were assessed at baseline and follow-up visits. Results: Statistically significant increases in BCVA (vs. baseline) were observed at 2 months (mean +0.9; standard deviation +/- 0.6 lines), 4 months (+1.3; +/- 0.7), and 6 months (+1.2; +/- 0.7) after the initial combined intravitreal therapy in 96/106 patients. At 6 months, BCVA had deteriorated in 20 of 96 (20.8%) patients by
